Uso universal da vacina inativada contra poliomielite

Abstract

Objectives: To present an update on the status of poliomyelitis worldwide, number of cases per year, regions most affected by the disease, vaccines currently available, their risks and benefits, monovalent vaccine use, risks of disseminating a mutant virus in the community, progress that has been made in terms of worldwide eradication and the World Health Organizations (WHO) proposals in this transition period between global eradication and the post-eradication period. Summary of the findings: In 1988, the WHO established the goal of eradicating the disease and interrupting transmission of the wild virus globally. Since then, there has been a dramatic decline of the disease, although in 2005 there were still some countries considered endemic and others where polio returned on account of imported viruses. The vaccines used worldwide are the classical tOPV and IPV, and in this eradication process, the use of mOPV vaccines has been encouraged in places where only one type of poliovirus circulates. In addition to spreading the virus in the community, the OPV vaccines may, however, cause paralyses by reversal of the neurovirulence process.Conclusions: For a world free of poliomyelitis disease, it would be necessary to interrupt circulation of the virus, which will only be possible if the OPV virus were to be discontinued, in accordance with the WHO proposals for this transition period and the post-eradication period.

Vigilância de eventos adversos pós-vacinação e segurança de programas de imunização

“…59,95 Poliomyelitis epidemics associated with poliovirus derived from the oral vaccine have triggered a discussion of changes in immunization strategies. 41,49,89 The incidence and intensity of AEFIs vary according to the characteristics of the vaccine, vaccinee, and vaccination mode.These are often mild, rapidly selflimiting disorders; however, more severe reactions do occasionally occur.The mechanisms of these reactions are not fully understood. 110 Given the relevance of immunobiologicals to public health, the World Health Organization (WHO)'s Department of Immunization, Vaccines, and Biologicals implemented the Immunization Safety Priority Project in 1999.In 2003, a wide-ranging system was implemented to ensure the safety of vaccines administered as part of national immunization programs.…”